Effect of intravenous metoprolol on reversible obstructive airways disease

Thomas A. Abraham, Faysal M. Hasan, Paul E Fenster, Frank I. Marcus

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We gave increasing doses of metoprololintravenously to seven subjects with stable chronic obstructive pulmonary disease (COPD) who were also receiving their usual bronchodilators. Six of the seven tolerated up to 0.2 mg/kg metoprolol without adverse effects, although there were declines in forced expiratory volume in 1 sec (FEV1) At 0.15 mg/kg mean FEV1 fell 12% (p < 0.025), and at 0.2 mglkg mean decline in FEV1 was 15% (p < 0.01). These findings suggest that 0.2 mg/kg metoprolol may be given intravenously to most patients with COPD in addition to previously administered bronchodilators without precipitating clinically significant adverse effects. Any side effects that develop can be reversed by beta agonists.

Original languageEnglish (US)
Pages (from-to)582-587
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume29
Issue number5
StatePublished - May 1981

Fingerprint

Metoprolol
Forced Expiratory Volume
Bronchodilator Agents
Chronic Obstructive Pulmonary Disease

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of intravenous metoprolol on reversible obstructive airways disease. / Abraham, Thomas A.; Hasan, Faysal M.; Fenster, Paul E; Marcus, Frank I.

In: Clinical Pharmacology and Therapeutics, Vol. 29, No. 5, 05.1981, p. 582-587.

Research output: Contribution to journalArticle

Abraham, Thomas A. ; Hasan, Faysal M. ; Fenster, Paul E ; Marcus, Frank I. / Effect of intravenous metoprolol on reversible obstructive airways disease. In: Clinical Pharmacology and Therapeutics. 1981 ; Vol. 29, No. 5. pp. 582-587.
@article{fdccbd4dc6a948bdbcfaaa12edf0411c,
title = "Effect of intravenous metoprolol on reversible obstructive airways disease",
abstract = "We gave increasing doses of metoprololintravenously to seven subjects with stable chronic obstructive pulmonary disease (COPD) who were also receiving their usual bronchodilators. Six of the seven tolerated up to 0.2 mg/kg metoprolol without adverse effects, although there were declines in forced expiratory volume in 1 sec (FEV1) At 0.15 mg/kg mean FEV1 fell 12{\%} (p < 0.025), and at 0.2 mglkg mean decline in FEV1 was 15{\%} (p < 0.01). These findings suggest that 0.2 mg/kg metoprolol may be given intravenously to most patients with COPD in addition to previously administered bronchodilators without precipitating clinically significant adverse effects. Any side effects that develop can be reversed by beta agonists.",
author = "Abraham, {Thomas A.} and Hasan, {Faysal M.} and Fenster, {Paul E} and Marcus, {Frank I.}",
year = "1981",
month = "5",
language = "English (US)",
volume = "29",
pages = "582--587",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Effect of intravenous metoprolol on reversible obstructive airways disease

AU - Abraham, Thomas A.

AU - Hasan, Faysal M.

AU - Fenster, Paul E

AU - Marcus, Frank I.

PY - 1981/5

Y1 - 1981/5

N2 - We gave increasing doses of metoprololintravenously to seven subjects with stable chronic obstructive pulmonary disease (COPD) who were also receiving their usual bronchodilators. Six of the seven tolerated up to 0.2 mg/kg metoprolol without adverse effects, although there were declines in forced expiratory volume in 1 sec (FEV1) At 0.15 mg/kg mean FEV1 fell 12% (p < 0.025), and at 0.2 mglkg mean decline in FEV1 was 15% (p < 0.01). These findings suggest that 0.2 mg/kg metoprolol may be given intravenously to most patients with COPD in addition to previously administered bronchodilators without precipitating clinically significant adverse effects. Any side effects that develop can be reversed by beta agonists.

AB - We gave increasing doses of metoprololintravenously to seven subjects with stable chronic obstructive pulmonary disease (COPD) who were also receiving their usual bronchodilators. Six of the seven tolerated up to 0.2 mg/kg metoprolol without adverse effects, although there were declines in forced expiratory volume in 1 sec (FEV1) At 0.15 mg/kg mean FEV1 fell 12% (p < 0.025), and at 0.2 mglkg mean decline in FEV1 was 15% (p < 0.01). These findings suggest that 0.2 mg/kg metoprolol may be given intravenously to most patients with COPD in addition to previously administered bronchodilators without precipitating clinically significant adverse effects. Any side effects that develop can be reversed by beta agonists.

UR - http://www.scopus.com/inward/record.url?scp=0019409413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019409413&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 582

EP - 587

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -